EL
Center for Complex Arrhythmias
In fiscal year 2017, patients with complex heart rhythm disorders from throughout the region continued to seek
the medical expertise and technology offered at the Center for Complex Arrhythmias (CCA) at Baylor Hamilton
Heart and Vascular Hospital, a part of Baylor Heart and Vascular Services at Dallas. A nationally recognized
team of health care professionals supported by advanced equipment and resources evaluate, treat and care
for patients with heart rhythm disorders.
The team consists of trained cardiac electrophysiologists
– cardiologists with intensive training in evaluating
and treating heart arrhythmias on the medical staff at
Baylor Hamilton Heart and Vascular Hospital – along
with experienced nurse practitioners and nurses. Patients
benefit from accurate diagnoses and treatment of irregular
heart beat conditions such as atrial fibrillation, ventricular
tachycardia, atrial flutter, atrial tachycardia, PACs and
PVCs, and other related arrhythmias.
The Center for Complex Arrhythmias (CCA) is a trusted
resource for patients, providing information on heart
arrhythmias and evidence-based treatment options
including medication therapy, catheter-based procedures
and surgery. Specialized interventions support the CCA’s
dedication to innovation, including:
• 3D mapping for complex arrhythmia ablation
• Transcatheter ablation therapy, radiofrequency
ablation and cryoablation
• Cardiac resynchronization therapy
• Left atrial appendage closure
40
• Pacemaker and implantable cardioverter
defibrillator (ICD) device implantation
• Laser-assisted lead extraction
In addition to CCA’s commitment to innovation and
outstanding outcomes for patients, the Center has played
a pivotal role in clinical research – studies that have led to
the development and approval of many practical, leading-
edge interventions. For example, Baylor Hamilton Heart
and Vascular Hospital has continued to evaluate patients
in a study to monitor the safety and effectiveness of the
WATCHMAN™ Left Atrial Appendage Closure Device.
Based on outstanding results, the device received FDA
approval for general use with patients at high risk of
developing blood clots in the left atrial appendage. The
device prevents clots from traveling to the brain and
triggering a stroke. This new intervention offers a feasible
alternative to patients taking blood thinners on a long-term
basis. Through the CCA, patients have access to clinical
research trials examining new devices and treatment
methods for cardiac arrhythmias and are evaluated to
determine if they are candidates for a clinical trial.
With a focus on patient-centered care, referring physicians
remain a vital part of the treatment team. Members of
the CCA health care team stay in close and frequent
communication with referring physicians about treatment
plans for their patients. For information